Alpha-mangostin and nab-paclitaxel in breast cancer cell models: improved antitumor efficacy through combination therapy.

Abstract

In the pursuit of more effective breast cancer therapies, the investigation of interactions between novel compounds and established chemotherapeutics has become increasingly important. This study investigates the combinatory effects of alpha-mangostin (α-MG) and nab-paclitaxel on MCF-7 and MDA-MB-231 cell lines, utilizing the xCELLigence RTCA system for continuous real-time cellular analysis, BrdU incorporation assays for proliferation assessment, and the quantification of mitotic activity and caspase-3/7 levels to elucidate apoptotic mechanisms. Our findings demonstrate that both α-MG and nab-paclitaxel independently induce significant inhibition of cellular proliferation and modulate cell cycle dynamics over a 24 to 72-hour period. Notably, when combined, these agents exhibit a pronounced enhancement of cell cycle inhibition and apoptosis, surpassing the effects observed with monotherapy. This potentiation effect suggests that α-MG augments the therapeutic efficacy of nab-paclitaxel, potentially allowing for reduced dosages in clinical applications. The study underscores the potential of α-MG as an adjuvant in breast cancer treatment, offering a promising strategy to optimize therapeutic regimens, minimize adverse effects, and improve patient outcomes in clinical oncology.